Samsrita Labs Past Earnings Performance
Past criteria checks 0/6
Samsrita Labs has been growing earnings at an average annual rate of 43.9%, while the Life Sciences industry saw earnings growing at 8.8% annually. Revenues have been declining at an average rate of 107.4% per year.
Key information
43.9%
Earnings growth rate
47.7%
EPS growth rate
| Life Sciences Industry Growth | 11.2% |
| Revenue growth rate | -107.4% |
| Return on equity | -6.7% |
| Net Margin | -3,841.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Samsrita Labs makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -8 | 1 | 0 |
| 30 Sep 23 | 0 | -8 | 1 | 0 |
| 30 Jun 23 | 0 | -7 | 1 | 0 |
| 31 Mar 23 | 0 | -7 | 1 | 0 |
| 31 Dec 22 | 0 | 15 | 2 | 0 |
| 30 Sep 22 | 0 | 15 | 2 | 0 |
| 30 Jun 22 | 0 | 15 | 2 | 0 |
| 31 Mar 22 | 0 | 15 | 1 | 0 |
| 31 Dec 21 | 0 | -1 | 1 | 0 |
| 30 Sep 21 | 0 | -3 | 1 | 0 |
| 30 Jun 21 | 0 | -5 | 2 | 0 |
| 31 Mar 21 | 0 | -8 | 3 | 0 |
| 31 Dec 20 | 3 | -12 | 12 | 0 |
| 30 Sep 20 | 7 | -13 | 10 | 0 |
| 30 Jun 20 | 10 | -16 | 12 | 0 |
| 31 Mar 20 | 14 | -20 | 18 | 0 |
| 31 Mar 19 | 20 | -23 | 21 | 0 |
| 31 Mar 18 | 6 | -10 | 8 | 0 |
| 31 Mar 17 | 13 | -8 | 4 | 0 |
| 31 Dec 16 | 25 | -1 | 1 | 0 |
| 30 Sep 16 | 28 | 0 | 2 | 0 |
| 30 Jun 16 | 25 | -1 | 1 | 0 |
| 31 Mar 16 | 37 | 0 | 1 | 0 |
| 30 Jun 15 | 55 | 0 | 0 | 0 |
| 31 Mar 15 | 40 | 0 | 1 | 0 |
Quality Earnings: 539267 is currently unprofitable.
Growing Profit Margin: 539267 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 539267 is unprofitable, but has reduced losses over the past 5 years at a rate of 43.9% per year.
Accelerating Growth: Unable to compare 539267's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 539267 is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-1.4%).
Return on Equity
High ROE: 539267 has a negative Return on Equity (-6.69%), as it is currently unprofitable.